ES2173433T3 - Procedimiento para la cristalizacion de losartan. - Google Patents

Procedimiento para la cristalizacion de losartan.

Info

Publication number
ES2173433T3
ES2173433T3 ES97913800T ES97913800T ES2173433T3 ES 2173433 T3 ES2173433 T3 ES 2173433T3 ES 97913800 T ES97913800 T ES 97913800T ES 97913800 T ES97913800 T ES 97913800T ES 2173433 T3 ES2173433 T3 ES 2173433T3
Authority
ES
Spain
Prior art keywords
losartan
procedure
crystallization
potassium
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97913800T
Other languages
English (en)
Inventor
Patrick Breen
Erik A Dienemann
Albert D Epstein
Karen A Larson
Michael T Kennedy
Hari Mahadevan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625804.1A external-priority patent/GB9625804D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2173433T3 publication Critical patent/ES2173433T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pile Receivers (AREA)

Abstract

EL POTASIO DE LOSARTAN ES UN ANTAGONISTA DE LA ANGIOTENSINA II QUE SE UTILIZA EN EL TRATAMIENTO DE LA HIPERTENSION Y DE LA INSUFICIENCIA CARDIACA GLOBAL (I). ESTA INVENCION SE REFIERE AL PROCEDIMIENTO DE CRISTALIZACION CONTROLADA DEL POTASIO DE LOSARTAN, EN EL CUAL SE UTILIZA UNA ADICION DE ANTIDISOLVENTE COMBINADA CON UNA SIEMBRA MASIVA DE FORMA QUE SE OBTENGA LA MORFOLOGIA DE CRISTAL DESEADA Y PROPIEDADES FISICAS GENERALES NECESARIAS PARA UNA FORMULACION SATISFACTORIA.
ES97913800T 1996-10-29 1997-10-24 Procedimiento para la cristalizacion de losartan. Expired - Lifetime ES2173433T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2932696P 1996-10-29 1996-10-29
GBGB9625804.1A GB9625804D0 (en) 1996-12-12 1996-12-12 Process for the crystallization of losartan

Publications (1)

Publication Number Publication Date
ES2173433T3 true ES2173433T3 (es) 2002-10-16

Family

ID=26310606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97913800T Expired - Lifetime ES2173433T3 (es) 1996-10-29 1997-10-24 Procedimiento para la cristalizacion de losartan.

Country Status (18)

Country Link
US (1) US5859258A (es)
EP (1) EP0937068B1 (es)
JP (1) JP3249827B2 (es)
CN (1) CN1101393C (es)
AR (1) AR010256A1 (es)
AT (1) ATE214388T1 (es)
AU (1) AU5089898A (es)
BR (1) BR9712390A (es)
CZ (1) CZ291672B6 (es)
DE (1) DE69711068T2 (es)
DK (1) DK0937068T3 (es)
EA (1) EA001046B1 (es)
ES (1) ES2173433T3 (es)
HR (1) HRP970565B1 (es)
PT (1) PT937068E (es)
SK (1) SK282875B6 (es)
TW (1) TW411338B (es)
WO (1) WO1998018787A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226372A (ja) 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
JP2002080354A (ja) * 2000-09-05 2002-03-19 Kao Corp 血圧降下剤組成物
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
SI21236A (sl) * 2001-05-18 2003-12-31 Aurobindo Pharma Limited Postopek kristalizacije losartan kalija
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
EP1634880A3 (en) 2002-04-29 2006-04-12 Teva Pharmaceutical Industries Ltd. Processes for preparing losartan and losartan potassium
US20040097568A1 (en) * 2002-07-29 2004-05-20 Dr. Reddy's Laboratories Limited Crystalline form of losartan potassium
US20040171843A1 (en) * 2002-10-17 2004-09-02 Igor Lifshitz Process for preparing losartan potassium with improved flow ability
AU2003278422A1 (en) * 2002-10-31 2004-05-25 Ranbaxy Laboratories Limited Amorphous form of losartan potassium
SI1589966T1 (sl) * 2003-01-30 2011-06-30 Lek Pharmaceuticals D.D. Postopek čiščenja losartana
WO2004076442A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
WO2005066158A2 (en) * 2004-01-06 2005-07-21 Ipca Laboratories Limited An improved process for the synthesis of losartan potassium
WO2006000564A1 (en) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
ITMI20050551A1 (it) * 2005-04-01 2006-10-02 Dipharma Spa Forma cristallina alfa di losartan potassio
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5206374A (en) * 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5130439A (en) * 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
JPH08500323A (ja) 1991-11-18 1996-01-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Ａ▲ｉｉ▼受容体アンタゴニストの合成のためのテトラゾリルフェニルボロン酸中間体
US5310928A (en) * 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
EP0736021A4 (en) * 1993-12-23 1997-04-02 Merck & Co Inc LOSARTAN POLYMORPH AND METHOD FOR PRODUCING FORM II LOSARTAN

Also Published As

Publication number Publication date
AR010256A1 (es) 2000-06-07
US5859258A (en) 1999-01-12
HRP970565A2 (en) 1998-08-31
CZ151599A3 (cs) 1999-10-13
DE69711068T2 (de) 2002-09-12
EP0937068B1 (en) 2002-03-13
SK57099A3 (en) 2000-02-14
CZ291672B6 (cs) 2003-04-16
WO1998018787A1 (en) 1998-05-07
DE69711068D1 (de) 2002-04-18
HRP970565B1 (en) 2003-02-28
JP2000504343A (ja) 2000-04-11
JP3249827B2 (ja) 2002-01-21
SK282875B6 (sk) 2003-01-09
DK0937068T3 (da) 2002-05-21
EA199900427A1 (ru) 1999-10-28
TW411338B (en) 2000-11-11
ATE214388T1 (de) 2002-03-15
EP0937068A1 (en) 1999-08-25
PT937068E (pt) 2002-07-31
AU5089898A (en) 1998-05-22
CN1101393C (zh) 2003-02-12
EA001046B1 (ru) 2000-08-28
BR9712390A (pt) 1999-08-31
CN1241186A (zh) 2000-01-12

Similar Documents

Publication Publication Date Title
PA8620501A1 (es) Compuestos utiles en terapia
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
AR109995A2 (es) Método para inhibir la resorción ósea
UY27711A1 (es) Compuestos útiles en terapia
UY26689A1 (es) Activadores de glucocinasa que contienen hidantoina
ECSP077180A (es) Compuestos, composiciones y métodos
NO20055253L (no) Behandling av autoimmun sykdom i en pasient med utilstrekkelig respons pa en TNF-alfa-inhibitor
ES2167571T3 (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
PA8557401A1 (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
ES2169128T3 (es) Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos.
EA200100418A1 (ru) Комбинированная терапия с применением ингибитора фермента конверсии ангиотензина и антагониста альдостерона для снижения заболеваемости и смертности при сердечно-сосудистых заболеваниях
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
DK0951282T3 (da) Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
ES2060274T3 (es) Bloqueadores de receptores de angiotensina ii para el tratamiento de la hipertrofia cardiaca.
EA199900427A1 (ru) Способ кристаллизации лозартана
DE60323645D1 (de) Duschvorrichtung mit bräunungsvorrichtung
UY28630A1 (es) Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol
UY26975A1 (es) Inhibición de la dependencia de células tumorales del factor de crecimiento.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
ES2182334T3 (es) Monohidrato de eprosartan.
CL2004001507A1 (es) Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.
ES2133390T3 (es) Derivados de triazolopirimidinas antagonistas de los receptores de la angiotensina ii.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 937068

Country of ref document: ES